治疗斑块状银屑病的新药:ixekizumab

A new drug for treatment of plaque psoriasis: ixekizumab

ixekizumab为一种人源性单克隆Ig G抗体,白细胞介素17A与银屑病等严重炎症性疾病密切相关,ixekizumab能够抑制白细胞介素17A的作用。美国FDA已经批准ixekizumab用于斑块状银屑病的治疗。本品常见不良反应包括恶心、注射部位反应、上呼吸道感染、皮肤和口腔真菌感染、鼻炎、结膜炎及炎症性肠病等。

Ixekizumab is a humanised monoclonal immunoglobulin G antibody. Interleukin-17A is a proinflammatory cytokine that has a role in the development of several inflammatory conditions, including psoriasis. Ixekizumab is a specific inhibitor of interleukin-17A. It has been approved in the USA for the treatment of plaque psoriasis. The most common adverse events of ixekizumab were nausea, injection site reactions, upper respiratory tract infections, tinea infections, oral candidiasis, rhinitis, conjunctivitis, inflammatory bowel disease and so on.